Ocuphire Pharma News

OCUPDelisted Stock  USD 1.13  0.06  5.04%   
Slightly above 62% of Ocuphire Pharma's investor base is looking to short. The analysis of current outlook of investing in Ocuphire Pharma suggests that many traders are alarmed regarding Ocuphire Pharma's prospects. Ocuphire Pharma's investing sentiment overview a quick insight into current market opportunities from investing in Ocuphire Pharma. Many technical investors use Ocuphire Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
over six months ago at news.google.com         
Ocuphire Pharma Engages Investors with Presentation Update - TipRanks.com - TipRanks
Google News at Macroaxis
over six months ago at news.google.com         
Ocuphire Pharma, Inc. CFO Nirav S. Jhaveri Buys 10000 Shares - Defense World
Google News at Macroaxis
over six months ago at investing.com         
Ocuphire Pharma CFO acquires 21,000 worth of company stock
Investing News at Macroaxis
over six months ago at investing.com         
Ocuphire Pharma COO acquires 4.1k in company stock
Investing News at Macroaxis
over six months ago at news.google.com         
Acquisition by Jhaveri Nirav S. of 10000 shares of Ocuphire Pharma at 2.1 subject to Rule 16b-3
Google News at Macroaxis
over six months ago at news.google.com         
Ocuphire Pharma CEO buys 49,050 in company stock By Investing.com - Investing.com
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Acquisition by Magrath George of 25000 shares of Ocuphire Pharma at 1.962 subject to Rule 16b-3
Macroaxis News
over six months ago at simplywall.st         
Ocuphire Pharma, Inc. Shares May Have Slumped 26 percent But Getting In Cheap Is Still Unlikely
Simply Wall St News at Macroaxis
over six months ago at investorplace.com         
OCUP Stock Earnings Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023
sbwire news
over six months ago at news.google.com         
HC Wainwright Weighs in on Ocuphire Pharma, Inc.s Q1 2024 Earnings - MarketBeat
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Earnings Update Ocuphire Pharma, Inc. Just Reported And Analysts Are Trimming Their Forecasts
Yahoo News
over six months ago at finance.yahoo.com         
Ocuphire Pharma Full Year 2023 Earnings Misses Expectations
Yahoo News
over six months ago at simplywall.st         
Ocuphire Pharma, Inc.s Stock Has Been Sliding But Fundamentals Look Strong Is The Market Wrong?
Simply Wall St News at Macroaxis
over six months ago at finance.yahoo.com         
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corpo...
Yahoo News
over six months ago at seekingalpha.com         
Ocuphire Pharma GAAP EPS of -0.21 misses by 0.21, revenue of 1.69M misses by 4.27M
seekingalpha News
Far too much social signal, news, headlines, and media speculation about Ocuphire Pharma that are available to investors today. That information is available publicly through Ocuphire media outlets and privately through word of mouth or via Ocuphire internal channels. However, regardless of the origin, that massive amount of Ocuphire data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ocuphire Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ocuphire Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ocuphire Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ocuphire Pharma alpha.

Ocuphire Pharma Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Intellia Therapeutics, Inc. Reports Q2 Loss, Lags Revenue Estimates
08/08/2024
2
Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update
08/13/2024
3
Analyst Forecasts For Ocuphire Pharma, Inc. Are Surging Higher
08/19/2024
4
Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75 percent for Presbyopia
09/05/2024
5
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75for Pharmacologically-Induced Mydriasis in Ophthalmology
09/30/2024
6
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal
10/23/2024
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Other Consideration for investing in Ocuphire Stock

If you are still planning to invest in Ocuphire Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ocuphire Pharma's history and understand the potential risks before investing.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios